Movement Alert｜BeOne Medicines Rises 3.19% in Regular Trading, Brukinsa MANGROVE Phase 3 Data and New Buy Rating Drive Momentum

Market Focus11:18

On July 10, BeOne Medicines (06160.HK) rose 3.19% in regular trading, trading at 187.5 HKD/share, with turnover of approximately 3.7 billion HKD. The rally was driven by continued catalysis from Brukinsa clinical data and a strong biotech sector linkage.

On the news front, the company's core product Brukinsa (zanubrutinib) achieved the primary endpoint in the MANGROVE Phase 3 trial evaluating a chemotherapy-free regimen as first-line treatment for mantle cell lymphoma. The combination of Brukinsa plus rituximab reduced disease progression or death risk by 43% versus standard immunochemotherapy (HR=0.57). BeOne Medicines plans to pursue global regulatory submissions in the second half of the year.

Additionally, Huafu Securities recently initiated coverage on BeOne Medicines with a Buy rating and a target price of 297.44 HKD, citing the company's entry into a new era of multi-curve growth, with solid tumor pipeline products advancing into pivotal clinical stages as a second growth driver. Within the Biotechnology sector, peers including Akeso rose 6.29%, Innovent Bio rose 5.21%, and Remegen rose 7.57%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156056676?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 11:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156056676","market":"us","top_or_hot":-1,"title":"Movement Alert｜BeOne Medicines Rises 3.19% in Regular Trading, Brukinsa MANGROVE Phase 3 Data and New Buy Rating Drive Momentum","media":"Market Focus","content":"<p><p>On July 10, BeOne Medicines (06160.HK) rose 3.19% in regular trading, trading at 187.5 HKD/share, with turnover of approximately 3.7 billion HKD. The rally was driven by continued catalysis from Brukinsa clinical data and a strong biotech sector linkage.</p><p>On the news front, the company's core product Brukinsa (zanubrutinib) achieved the primary endpoint in the MANGROVE Phase 3 trial evaluating a chemotherapy-free regimen as first-line treatment for mantle cell lymphoma. The combination of Brukinsa plus rituximab reduced disease progression or death risk by 43% versus standard immunochemotherapy (HR=0.57). BeOne Medicines plans to pursue global regulatory submissions in the second half of the year.</p><p>Additionally, Huafu Securities recently initiated coverage on BeOne Medicines with a Buy rating and a target price of 297.44 HKD, citing the company's entry into a new era of multi-curve growth, with solid tumor pipeline products advancing into pivotal clinical stages as a second growth driver. Within the Biotechnology sector, peers including Akeso rose 6.29%, Innovent Bio rose 5.21%, and Remegen rose 7.57%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BeOne Medicines Rises 3.19% in Regular Trading, Brukinsa MANGROVE Phase 3 Data and New Buy Rating Drive Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BeOne Medicines Rises 3.19% in Regular Trading, Brukinsa MANGROVE Phase 3 Data and New Buy Rating Drive Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-10 11:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 10, BeOne Medicines (06160.HK) rose 3.19% in regular trading, trading at 187.5 HKD/share, with turnover of approximately 3.7 billion HKD. The rally was driven by continued catalysis from Brukinsa clinical data and a strong biotech sector linkage.</p><p>On the news front, the company's core product Brukinsa (zanubrutinib) achieved the primary endpoint in the MANGROVE Phase 3 trial evaluating a chemotherapy-free regimen as first-line treatment for mantle cell lymphoma. The combination of Brukinsa plus rituximab reduced disease progression or death risk by 43% versus standard immunochemotherapy (HR=0.57). BeOne Medicines plans to pursue global regulatory submissions in the second half of the year.</p><p>Additionally, Huafu Securities recently initiated coverage on BeOne Medicines with a Buy rating and a target price of 297.44 HKD, citing the company's entry into a new era of multi-curve growth, with solid tumor pipeline products advancing into pivotal clinical stages as a second growth driver. Within the Biotechnology sector, peers including Akeso rose 6.29%, Innovent Bio rose 5.21%, and Remegen rose 7.57%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1156056676","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156056676","pubTimestamp":1783653495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 10, BeOne Medicines (06160.HK) rose 3.19% in regular trading, trading at 187.5 HKD/share, with turnover of approximately 3.7 billion HKD. The rally was driven by continued catalysis from...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"走势警报|BeOne Medicines 常规交易上涨 3.19%，Brukinsa MANGROVE 第三阶段数据和新的买入评级推动势头","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On July 10, BeOne Medicines (06160.HK) rose 3.19% in regular trading, trading at 187.5 HKD/share, with turnover of approximately 3.7 billion HKD. The rally was driven by continued catalysis from Brukinsa clinical data and a strong biotech sector linkage.On the news front, the company's core product Brukinsa (zanubrutinib) achieved the primary endpoint in the MANGROVE Phase 3 trial evaluating a chemotherapy-free regimen as first-line treatment for mantle cell lymphoma. The combination of Brukinsa plus rituximab reduced disease progression or death risk by 43% versus standard immunochemotherapy (HR=0.57). BeOne Medicines plans to pursue global regulatory submissions in the second half of the year.Additionally, Huafu Securities recently initiated coverage on BeOne Medicines with a Buy rating and a target price of 297.44 HKD, citing the company's entry into a new era of multi-curve growth, with solid tumor pipeline products advancing into pivotal clinical stages as a second growth driver. Within the Biotechnology sector, peers including Akeso rose 6.29%, Innovent Bio rose 5.21%, and Remegen rose 7.57%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156056676","isCrawlerRequest":true}